Trial Profile
Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) with IPI-145
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2014
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 08 Jan 2014 New siurce identified and intergrated (ClinicalTrials.gov record; NCT02028039)
- 23 Nov 2013 New trial record